-
The inter-provincial direct settlement rate of hospitalization expenses at the end of the "14th Five-Year Plan" period strives to reach more than 70%
Time of Update: 2021-12-04
In order to expand the benefits of this reform, the measures proposed at this meeting include: improving relevant policies, simplifying procedures to facilitate remote filing of insured persons, steadily increasing the rate of direct settlement of hospitalization expenses across provinces, and striving to reach 70% by the end of the "14th Five-Year Plan" period.
-
Favorable policies come out frequently, and the rehabilitation industry will usher in a period of development opportunities
Time of Update: 2021-12-04
, To bring a certain patient diversion effect to the back-end rehabilitation medical care, and promote the development of rehabilitation medical disciplines; it will also quickly release the demand for related medical equipment and equipment during the construction of rehabilitation departments of secondary medical institutions and below .
-
Treating a variety of neurological diseases about 2.6 billion US dollars to help develop selective GPCR agonists
Time of Update: 2021-12-04
Recently, Neurocrine Biosciences and Sosei Heptares announced a strategic cooperation and licensing agreement to jointly develop new selective muscarinic receptor agonists for the treatment of schizophrenia, dementia and other neurological diseases .
-
The reshuffle of the pharmacy industry is accelerating, and single pharmacies will face major challenges
Time of Update: 2021-12-04
Therefore, the industry predicts that under the huge transformation and upgrading pressure of the current increase in industry concentration, a large number of monomer pharmacies will be eliminated at an accelerated pace.
-
Domestic cell therapy is in full swing, isolator is expected to usher in a market space of nearly 10 billion yuan
Time of Update: 2021-12-03
The domestic cell therapy isolator is expected to usher in a market space of nearly 10 billion yuan (Source: Pharmaceutical Network) What is a cell culture isolator?
-
The Internet medical market has a high growth trend, and the performance of related companies has increased significantly
Time of Update: 2021-12-03
Ali Health stated that the increase in revenue was mainly due to the rapid growth of its pharmaceutical self-operated business .
-
The pharmaceutical packaging equipment market continues to expand, and shortcomings are urgently needed
Time of Update: 2021-12-03
Analysts pointed out that pharmaceutical packaging machinery companies need to further make up for shortcomings, grasp the trend of automation and green development, and accelerate the upgrade to high-end equipment, in order to "share the cake" in the future market competition and accelerate the pace of domestic substitution .
-
Hengrui received clinical approval for many new drugs
Time of Update: 2021-12-03
On November 26, Hengrui issued an announcement that two clinical trial applications were approved by the National Food and Drug Administration: Carrelizumab combined with famitinib malate and paclitaxel for injection (albumin-bound) for the treatment of patients with advanced solid tumors An open, multi-center phase Ib/II clinical study; SHR-1701 injection combined with lenvatinib mesylate capsules vs.
-
China's innovative drugs spring is here
Time of Update: 2021-12-03
Note: Count the number of new drugs approved for the first time in the dimensions of [ingredients-dosage forms-enterprises]New drugs include first-in-class drugs and improved new drugs, the same belowAt the same time, the research and development of domestically produced Class 1 innovative drugs is also accelerating .
-
The results of the sixth batch of centralized procurement of medicines were announced: the highest drop of insulin was over 70%
Time of Update: 2021-12-03
89 yuan/piece, a decrease of 64%, and the proposed company is Ganli Pharmaceutical; and among the three generations of insulin, the lowest proposed bid price for meal insulin analogues is 19.
-
The prospect of domestic gene sequencing is broad, and related companies are accelerating the layout
Time of Update: 2021-12-03
The industry predicts that by 2022, China's genetic testing market is expected to exceed 30 billion yuan, and affected by this, the performance of related companies may also usher in a new round of growth .
-
Proposed selection results of national centralized drug procurement (insulin special project)
Time of Update: 2021-12-03
622, Jumen Road, Huangpu District, Shanghai Phone: 021-31773244; 31773255; 31773266 Attachment: Proposed selection result table for the national centralized drug procurement (insulin special item) National Organization Drug Joint Procurement OfficeDrug Drug Drug Purchase Purchase Purchase November 26, 2021
-
What are the highlights of the first domestically produced PD-L1?
Time of Update: 2021-12-03
On November 25, Envolimab, the strategic cooperation between Sidi Medicine, Corning Jerry and Simcere, was officially approved by the National Medical Products Administration, which means that the first domestically produced PD-L1 product will soon be on the market .
-
The sixth batch of centralized procurement of medicines, new progress is here!
Time of Update: 2021-12-03
This centralized drug procurement involves 81 varieties of insulin products, involving Jiangsu Wanbang, Novo Nordisk, Tonghua Dongbao, Ganli Pharmaceutical, United Laboratories, Sanofi, Eli Lilly, Hefei Tianmai, Poland Baitong (domestic production The enterprise/sub-packaging plant is a total of 9 domestic and foreign enterprises including Harbin Yuheng Pharmaceutical/Hefei Yifan) and Yichang Dongyangguang .
-
From 3 fixed-point production pilots to 57 information monitoring: the history of changes in drug shortage intervention management
Time of Update: 2021-12-03
The actual increase, and taking into consideration the wishes of the desacetyl-lanoside injection manufacturers, the above-mentioned two varieties will no longer be subject to fixed-point production, and they will be included in the key monitoring scope of shortage drugs; methimazole tablets (5mg), lobe hydrochloride Lin injection (1ml: 3mg) will continue to implement the pilot project of designated production for one year .
-
Merck's new crown oral drug effective rate drops to 30%
Time of Update: 2021-12-03
On November 26, Merck and Ridgeback announced updated clinical data for the new crown oral drug Molnupiravir for the treatment of mild to moderate new crowns .
In the interim analysis, Molnupiravir reduced the risk of hospitalization or death by approximately 50% ; on the 29th day after randomization, 7.
-
Revenue of 61 Chinese medicine companies increased by nearly 13%. It is recommended to pay attention to two pharmaceutical companies
Time of Update: 2021-12-03
In the first three quarters of 2021, the total operating income of 61 traditional Chinese medicine companies increased by nearly 13% year-on-year .
According to data, in 2021Q1-Q3, the total operating income of 61 traditional Chinese medicine companies increased by 12.
-
A pharmaceutical company was punished for using unqualified Chinese medicinal materials to produce!
Time of Update: 2021-12-03
According to the administrative penalty decision, the type of administrative punishment for a pharmaceutical company in Fujian for the production and sale of inferior drugs such as Baixian Pi, Qianhu, and Epimedium and according to relevant regulations, the Office decided to impose the following penalties on the parties: The Office ordered the parties immediately Corrected illegal activities, confiscated 2 kilograms of inferior medicine Qianhu, 12.
-
The National Health Commission issued a document to check the results of the national mutual recognition era is coming!
Time of Update: 2021-12-03
In terms of powers, the draft for comments is clear, and the State Council's health authority is responsible for the management of mutual recognition of inspection results of medical institutions across the country .
-
Innovative pharmaceutical companies have launched more than 30 transactions during the year
Time of Update: 2021-12-03
On August 8, 2021, Rongchang Biologics reached a cooperation agreement with Seattle Genes to develop and commercialize its new ADC drug, vedicitumumab.
The drug has received conditional marketing approval in China for the treatment of locally advanced metastatic gastric cancer .
